Supplementary Table 1. Clinicopathologic characteristics of melanoma patients

Patients ID	Age	Sex	Stage	Survival	Follow-up time (months)
1	40	F	I	Yes	58
2	39	F	I	No	46
3	42	F	I	Yes	55
4	67	M	II	Yes	57
5	62	F	III	Yes	58
6	68	F	II	No	21
7	71	M	III	Yes	59
8	61	M	III	No	16
9	65	F	II	Yes	59
10	35	F	II	Yes	59
11	74	F	III	No	28
12	53	F	III	No	5
13	43	M	I	Yes	59
14	78	M	II	Yes	58
15	65	F	II	Yes	57
16	59	F	III	Yes	57
17	54	M	II	No	18
18	65	M	II	Yes	56
19	56	M	I	Yes	58
20	59	M	II	No	18
21	73	M	I	Yes	57
22	57	F	II	Yes	56
23	59	F	I	Yes	57
24	72	F	II	No	32
25	47	M	I	Yes	59
26	63	M	III	No	20
27	63	M	II	No	32
28	33	M	III	No	41
29	44	F	III	No	12
30	48	M	II	Yes	55

Supplementary Table 2. Clinicopathologic characteristics of melanocytic nevus controls

Patients ID	Age	Sex
1	63	F
2	57	F
3	49	F
4	69	F
5	67	M
6	62	F
7	54	M
8	38	F
9	35	F
10	76	F
11	49	F
12	42	M
13	46	M
14	55	F
15	64	M
16	68	F
17	76	M
18	71	M
19	56	M
20	63	M

Supplementary Table 3. The comparisons of clinical characteristics between melanoma patients and controls

Characteristics	Melanoma	Control	χ^2	*p* value*
Age			0.053	0.817
< 60 y	16	10		
> 60 y	14	10		
Gender			0.120	0.729
Male	15	9		
Female	15	11		

*p value was acquired by Pearson chi-square test.



Supplementary Figure 1. MHENCR expression in melanoma with different clinical characteristics. A: MHENCR expression levels in 30 malignant melanoma tissues with different age were measured by qPCR. P = 0.819 by Mann-Whitney U test. B: MHENCR expression levels in 30 melanoma tissues with different sex were measured by qPCR. P = 0.648 by Mann-Whitney U test.

A

```
1   TGTCAGCTCC TAACGCCGCA GGTTCCTCCT GGTCCCCGAG GCCCCCGGTC GGGCGTTGCC
61  TGCCCCGCGC GGGCGGCCGG GCCGAGGGAC GATGGTCAGT GGACGGACGG CGCCAGGGAG
121 CAGTGCCCAC GCGCGGCAGG GCGGTACCTT CAGGCCTCCA GAGGCTGGGG CTGGCTCTGT
181 TGGCCTCTGT GCTGGGTTTC TTCCTCTGCA CCGCAGGACT GGCTCTCCTG ACCTCTCCAG
241 GTGTCATCGA ACACCCTTGT GCTTGCTGTC ACCCGCTGCC TGTCTGCAGG ATCCCGGATT
301 CCGTATCAGG GGACCGAAAT TAGTCGGAAA ATAGGAAGCA GGTGCTCGCT TGGATGGAAC
361 CCTGACCCTG TGCTCACACT TGTAGGAGGA GGGCTCTGCA GGCCGCCTCC CGGAACGGGA
421 GGTTCCCAAG CCACTGCACT TCGGAGGGGC TGTAATTAGA GTTGCACATT CATTCAGTTC
481 CCAGTAAAGT AGAACGTGCT CCAGCCAGTG AGGAAAAGGT GTTTTTAAAA ATTAGATTGG
541 CCGAGTGCGG TGGCTCATGC CTTTTACCTC AACACTTTGG GAGACAAAGG TGGGAGGATC
601 ACCTGTGGCC AGGAGTTCAA GACCAGCCTG GGCAACAGAG CCTGTCTCTG GGGAAGAATA
661 AAAAAAAAAA TTGAGCCTTT GTCAGTGCTA CTATTTTATT ATCTGGTAAA TATGAGAGGG
721 TTCACGCGGT CTATGTGTGT CATTTATCTG AGTTTGCCTA TCGTCACGTT TTGGAAATAA
781 ATGTCAATAA AGTCG
```

B



Supplementary Figure 2. The full-length sequences and subcellular localization of MHENCR in melanoma cells. A: The full-length sequences of MHENCR. B: MHENCR subcellular location in A375 cells was determined by cytoplasmic and nuclear RNA purification, followed by qPCR detection. U6 and β-actin were used as nuclear and cytoplasmic controls, respectively. n = 3.